findmyKOL
Clinical trialNCT05988918Active, not recruitingPhase 2Interventional

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

SponsorUniversity of Michigan Rogel Cancer CenterEnrollment17Adenosquamous CarcinomaGastrointestinal Neuroendocrine CarcinomaGastrointestinal Neuroendocrine TumorNeuroendocrine Prostate CarcinomaPancreatic AdenocarcinomaPancreatic Neuroendocrine Carcinoma+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Rogel Cancer Center

    Ann Arbor, Michigan, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Apr 2024
Primary completion
21 Feb 2026
Completion
31 Aug 2027
Last update posted
14 May 2026
Registered enrollment
17
Registry id
NCT05988918

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.